摘要
目的观察不同抗病毒药物治疗前后乙肝肝硬化失代偿期患者的血清白细胞介素-17(IL-17)的变化,分析不同抗病毒药物(替比夫定、恩替卡韦、替诺福韦)对乙肝肝硬化失代偿期患者血清IL-17的影响及意义。方法取2017年9月至2018年12月在我院门诊及病房使用抗病毒药物治疗前后乙肝肝硬化失代偿期患者血清,采用ELISA方法检测血清IL-17的水平,观察患者治疗前后血清IL-17及肝脏功能、乙肝DNA定量等变化。结果治疗前乙肝肝硬化患者血清中IL-17水平较正常值明显升高,经过不同抗病毒药物治疗后,替比夫定组IL-17明显下降,差异有统计学意义(P<0.05),恩替卡韦及替诺福韦组IL-17有所下降,但差异无统计学意义(P>0.05)。三组不同抗病毒药物治疗24周后,患者ALT复常率、HBV-DNA转阴率等方面进行比较,各组患者均有不同程度的改善,三组间比较差异无统计学意义(P>0.05)。结论替比夫定能降低乙肝肝硬化失代偿期患者血清IL-17水平。
Objective To investigate the changes of serum interleukin-17(IL-17)after treatment of different antiviral drugs(Tebivudine,Entecavir,Tenofovir)and to evaluate the effects of these antiviral drugs on serum IL-17in patients with decompensated hepatitis B cirrhosis.Methods From September 2017 to December 2018,serum was collected from out-and in-hospital patients with decompensated hepatitis B cirrhosis before and after treatment of antiviral drugs.Serum IL-17 was detected by ELISA,and liver functions and hepatitis B DNA quantification were measured.Results Before treatment of antiviral drugs,serum IL-17 level in patients with decompensated hepatitis B cirrhosis was significantly elevated compared to the normal values.After treatment of antiviral drugs,Tebivudine significantly decreased serum IL-17(P<0.05),and Entecavir and Tenofovir slightly decreased serum IL-17 but without significance(P>0.05).After 24-week treatment,ALT normalizing rate and HBV-DNA negative conversion ratio were improved in all three groups and antiviral drugs,and no significant differences were found among the three antiviral drugs(P>0.05).Conclusion Tebivudine could decrease the serum IL-17 in patients with decompensated hepatitis B cirrhosis.
作者
张笛
李贞茂
王治兰
高采平
李良平
Zhang Di;Li Zhenmao;Wang Zhilan(Department of Gastroenterology,Sichuan Academy of Medical Sciences and Sichuan Provincial People′s Hospital,Chengdu,Sichuan 610072,China)
出处
《四川医学》
CAS
2019年第10期990-992,共3页
Sichuan Medical Journal
基金
四川省卫计委课题(编号:17PJ048)
